Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has ...

Investing.com - JPMorgan initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an Overweight rating and set a price target of $29.00, analyst Brian Cheng said Monday. The target represents ...

Eikon went public in New York last month after selling 21.2 million shares in an IPO priced at $18 each. J.P. Morgan, Morgan Stanley, BofA Securities, Cantor and Mizuho were underwriters for the ...

Investing.com - Mizuho initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an outperform rating and set a price target of $26.00. The target represents nearly 90% upside from the current ...

Somer G. Anderson is CPA, doctor of accounting, and an accounting and finance professor who has been working in the accounting and finance industries for more than 20 years. Her expertise covers a ...

Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...

Artificial intelligence could lift euro zone productivity growth by more than 4 percentage points over the next decade, although a prolonged energy shock could slow progress, European Central Bank ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

We may earn commission from links on this page, but we only recommend products we love. Promise. Listen, I’ll be the first person to tell you that homemade face masks can be a little questionable.

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.